T-Helper Cell Subset Response Is a Determining Factor in COVID-19 Progression.
Adult
Aged
COVID-19
/ blood
Cytokines
/ blood
Disease Progression
Female
Humans
Immunity
Male
Middle Aged
Multivariate Analysis
Prospective Studies
SARS-CoV-2
/ immunology
T-Lymphocyte Subsets
/ immunology
T-Lymphocytes, Helper-Inducer
/ immunology
Th1 Cells
/ immunology
Th17 Cells
/ immunology
Th2 Cells
/ immunology
COVID-19
SARS-Cov2
T-helper
cytokines
immunity
Journal
Frontiers in cellular and infection microbiology
ISSN: 2235-2988
Titre abrégé: Front Cell Infect Microbiol
Pays: Switzerland
ID NLM: 101585359
Informations de publication
Date de publication:
2021
2021
Historique:
received:
31
10
2020
accepted:
25
01
2021
entrez:
15
3
2021
pubmed:
16
3
2021
medline:
25
3
2021
Statut:
epublish
Résumé
The immune response type organized against viral infection is determinant in the prognosis of some infections. This work has aimed to study Th polarization in acute COVID-19 and its possible association with the outcome through an observational prospective study. Fifty-eight COVID-19 patients were recruited in the Medicine Department of the hospital "12 de Octubre," 55 patients remaining after losses to follow-up. Four groups were established according to maximum degree of disease progression. T-helper cell percentages and phenotypes, analyzed by flow cytometer, and serum cytokines levels, analyzed by Luminex, were evaluated when the microbiological diagnosis (acute phase) of the disease was obtained. Our study found a significant reduction of %Th1 and %Th17 cells with higher activated %Th2 cells in the COVID-19 patients compared with reference population. A higher percent of senescent Th2 cells was found in the patients who died than in those who survived. Senescent Th2 cell percentage was an independent risk factor for death (OR: 13.88) accompanied by the numbers of total lymphocytes (OR: 0.15) with an AUC of 0.879. COVID-19 patients showed a profile of pro-inflammatory serum cytokines compared to controls, with higher levels of IL-2, IL-6, IL-15, and IP-10. IL-10 and IL-13 were also elevated in patients compared to controls. Patients who did not survive presented significantly higher levels of IL-15 than those who recovered. No significant differences were observed according to disease progression groups. The study has shown that increased levels of IL-15 and a high Th2 response are associated with a fatal outcome of the disease.
Identifiants
pubmed: 33718270
doi: 10.3389/fcimb.2021.624483
pmc: PMC7952877
doi:
Substances chimiques
Cytokines
0
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
624483Informations de copyright
Copyright © 2021 Gil-Etayo, Suàrez-Fernández, Cabrera-Marante, Arroyo, Garcinuño, Naranjo, Pleguezuelo, Allende, Mancebo, Lalueza, Díaz-Simón, Paz-Artal and Serrano.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Mil Med Res. 2020 Mar 13;7(1):11
pubmed: 32169119
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Physiology (Bethesda). 2020 Sep 1;35(5):288-301
pubmed: 32783610
J Immunol. 2008 Oct 15;181(8):5490-500
pubmed: 18832706
Cell Mol Immunol. 2020 May;17(5):533-535
pubmed: 32203188
Eur Cytokine Netw. 1998 Sep;9(3 Suppl):12-6
pubmed: 9831180
BMJ. 2003 Jun 21;326(7403):1358-62
pubmed: 12816821
Cytometry A. 2019 Jun;95(6):647-654
pubmed: 30714682
N Engl J Med. 2020 May 7;382(19):1787-1799
pubmed: 32187464
Ann Hematol. 2020 Jun;99(6):1419-1420
pubmed: 32382776
J Infect Dis. 2020 May 11;221(11):1762-1769
pubmed: 32227123
Immunology. 2010 Jun;130(2):166-71
pubmed: 20557575
Clin Microbiol Infect. 2020 Jul;26(7):948.e1-948.e3
pubmed: 32360780
Zhonghua Bing Li Xue Za Zhi. 2020 May 8;49(5):411-417
pubmed: 32172546
Front Microbiol. 2013 Sep 17;4:276
pubmed: 24062733
Sci Rep. 2016 May 05;6:25359
pubmed: 27146253
J Infect. 2020 Aug;81(2):e16-e25
pubmed: 32335169
Methods Mol Biol. 2017;1591:215-224
pubmed: 28349485
Clin Infect Dis. 2020 Jul 28;71(15):762-768
pubmed: 32161940
Immunol Today. 1996 Mar;17(3):138-46
pubmed: 8820272
J Allergy Clin Immunol. 2020 Oct;146(4):799-807.e9
pubmed: 32710975
Sci Immunol. 2020 Jun 26;5(48):
pubmed: 32591408
Infect Immun. 2004 Aug;72(8):4410-5
pubmed: 15271897
J Leukoc Biol. 1995 Mar;57(3):450-4
pubmed: 7884317
Nat Rev Immunol. 2020 Sep;20(9):529-536
pubmed: 32728222
Springer Semin Immunopathol. 1999;21(3):317-38
pubmed: 10666776
Cytometry A. 2020 Aug;97(8):772-776
pubmed: 32542842
J Clin Invest. 1998 Mar 15;101(6):1261-72
pubmed: 9502767
J Allergy Clin Immunol. 1997 Sep;100(3):348-55
pubmed: 9314347
Immunity. 2020 Jun 16;52(6):910-941
pubmed: 32505227
Front Microbiol. 2015 Oct 20;6:1153
pubmed: 26539181
Clin Exp Immunol. 2000 May;120(2):267-73
pubmed: 10792375
Nat Rev Immunol. 2020 May;20(5):271-272
pubmed: 32296135
JCI Insight. 2020 May 21;5(10):
pubmed: 32324595
Allergy. 2020 Jul;75(7):1824-1827
pubmed: 32330314
Microbes Infect. 2012 Mar;14(3):247-61
pubmed: 22064066
BMC Infect Dis. 2020 Dec 21;20(1):963
pubmed: 33349241
Immunol Rev. 2006 Jun;211:81-92
pubmed: 16824119
JCI Insight. 2020 Jun 18;5(12):
pubmed: 32427582
Crit Rev Immunol. 1998;18(3):153-84
pubmed: 9637409
J Immunol. 2002 Jul 1;169(1):340-9
pubmed: 12077263
J Med Virol. 2020 Nov;92(11):2768-2776
pubmed: 32543740
Immunol Today. 1993 Mar;14(3):107-11
pubmed: 8096699
Signal Transduct Target Ther. 2020 Mar 27;5(1):33
pubmed: 32296069
Eur Respir J. 2016 Jan;47(1):212-22
pubmed: 26541527
J Autoimmun. 2020 May;109:102433
pubmed: 32113704
J Microbiol Immunol Infect. 2020 Jun;53(3):368-370
pubmed: 32205092
Clin Immunol. 2020 Jun;215:108427
pubmed: 32325252
Proc Natl Acad Sci U S A. 2020 May 19;117(20):10970-10975
pubmed: 32350134
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Front Immunol. 2020 May 01;11:827
pubmed: 32425950
J Clin Invest. 2012 Aug;122(8):2967-82
pubmed: 22797302
Cell Rep Med. 2020 Sep 22;1(6):100081
pubmed: 32839763
Int Immunopharmacol. 2020 Jul;84:106504
pubmed: 32304994
Nature. 2020 Aug;584(7821):463-469
pubmed: 32717743
J Infect. 2016 Nov;73(5):468-475
pubmed: 27519621
J Immunol. 2002 Oct 15;169(8):4288-97
pubmed: 12370360
Sci Rep. 2020 Sep 28;10(1):15838
pubmed: 32985562
Viral Immunol. 2020 May;33(4):251-252
pubmed: 32348715
Microbes Infect. 2020 May - Jun;22(4-5):165-167
pubmed: 32305501
Cell Mol Immunol. 2020 May;17(5):541-543
pubmed: 32203186
J Immunol. 1998 Nov 15;161(10):5245-51
pubmed: 9820496
Immunol Rev. 2004 Jun;199:84-99
pubmed: 15233728
Cytokine. 1998 Oct;10(10):786-9
pubmed: 9811532
Lancet. 2020 Feb 15;395(10223):507-513
pubmed: 32007143
J Exp Med. 2020 Jun 1;217(6):
pubmed: 32353870
J Microbiol Immunol Infect. 2021 Feb;54(1):12-16
pubmed: 32425996
Int J Oral Sci. 2020 Feb 24;12(1):8
pubmed: 32094336
Dev Immunol. 1998;6(3-4):233-43
pubmed: 9814597
Nat Immunol. 2020 Oct;21(10):1146-1151
pubmed: 32855555
Clin Infect Dis. 2001 Jan;32(1):76-102
pubmed: 11118387
Clin Infect Dis. 2004 Oct 1;39(7):1071-5
pubmed: 15472864
AIDS. 1997 Jul 15;11(9):1075-88
pubmed: 9233453
J Immunol. 2000 Feb 15;164(4):1768-74
pubmed: 10657623
Clin Exp Immunol. 2004 Apr;136(1):95-103
pubmed: 15030519
Infection. 2021 Feb;49(1):15-28
pubmed: 32860214
Lancet. 2003 Apr 19;361(9366):1319-25
pubmed: 12711465
Annu Rev Immunol. 2010;28:445-89
pubmed: 20192806
Immunology. 2008 Mar;123(3):326-38
pubmed: 17983439
Int J Mol Sci. 2019 Jun 11;20(11):
pubmed: 31212601